Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Techne (TECH) Deferred Taxes (2016 - 2025)

Bio-Techne has reported Deferred Taxes over the past 17 years, most recently at -$72000.0 for Q4 2025.

  • Quarterly results put Deferred Taxes at -$72000.0 for Q4 2025, up 99.11% from a year ago — trailing twelve months through Dec 2025 was -$32.5 million (down 6.34% YoY), and the annual figure for FY2025 was -$51.1 million, down 29.56%.
  • Deferred Taxes for Q4 2025 was -$72000.0 at Bio-Techne, down from $5.3 million in the prior quarter.
  • Over the last five years, Deferred Taxes for TECH hit a ceiling of $5.4 million in Q3 2021 and a floor of -$32.3 million in Q2 2025.
  • Median Deferred Taxes over the past 5 years was -$5.8 million (2021), compared with a mean of -$6.8 million.
  • Biggest five-year swings in Deferred Taxes: skyrocketed 1296.24% in 2021 and later plummeted 2586.41% in 2023.
  • Bio-Techne's Deferred Taxes stood at $1.8 million in 2021, then tumbled by 187.51% to -$1.6 million in 2022, then tumbled by 571.03% to -$10.7 million in 2023, then rose by 24.68% to -$8.1 million in 2024, then skyrocketed by 99.11% to -$72000.0 in 2025.
  • The last three reported values for Deferred Taxes were -$72000.0 (Q4 2025), $5.3 million (Q3 2025), and -$32.3 million (Q2 2025) per Business Quant data.